Clinical trial
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia
NCT00313586 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- July 31, 2013
- Enrollment
- 197 (actual)
- Sites
- 234
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara, alkylating agent-related acute myeloid leukemia, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndrome, untreated adult acute myeloid leukemia